NCT02286414View on ClinicalTrials.gov

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over

CompletedOBSERVATIONAL

Enrollment

159

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions

Atrial Fibrillation

Interventions

DRUG

Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban

Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban

DRUG

Vitamin K antagonist: warfarin, fluindione, acenocoumarol

Exposure to vitamin K antagonist

Trial Locations (1)

75018

Assistance Publique Hôpitaux de Paris, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02286414 - Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over | Biotech Hunter | Biotech Hunter